JPH09500783A - シトシンデアミナーゼ（ｃｄ）遺伝子に基づく二機能性選択融合遺伝子 - Google Patents

シトシンデアミナーゼ（ｃｄ）遺伝子に基づく二機能性選択融合遺伝子

Info

Publication number
JPH09500783A
JPH09500783A JP7500787A JP50078795A JPH09500783A JP H09500783 A JPH09500783 A JP H09500783A JP 7500787 A JP7500787 A JP 7500787A JP 50078795 A JP50078795 A JP 50078795A JP H09500783 A JPH09500783 A JP H09500783A
Authority
JP
Japan
Prior art keywords
gene
cells
selection
neo
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP7500787A
Other languages
English (en)
Japanese (ja)
Inventor
ディー． ラプトン，スティーブン
Original Assignee
ターゲッティッド ジェネティクス コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ターゲッティッド ジェネティクス コーポレイション filed Critical ターゲッティッド ジェネティクス コーポレイション
Publication of JPH09500783A publication Critical patent/JPH09500783A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP7500787A 1993-05-21 1994-05-19 シトシンデアミナーゼ（ｃｄ）遺伝子に基づく二機能性選択融合遺伝子 Pending JPH09500783A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6638893A 1993-05-21 1993-05-21
US08/066,388 1993-05-21
PCT/US1994/005601 WO1994028143A1 (fr) 1993-05-21 1994-05-19 Genes de fusion selectables et bifonctionnels se basant sur le gene de cytosine-deaminase (cd)

Publications (1)

Publication Number Publication Date
JPH09500783A true JPH09500783A (ja) 1997-01-28

Family

ID=22069207

Family Applications (1)

Application Number Title Priority Date Filing Date
JP7500787A Pending JPH09500783A (ja) 1993-05-21 1994-05-19 シトシンデアミナーゼ（ｃｄ）遺伝子に基づく二機能性選択融合遺伝子

Country Status (5)

Country Link
EP (1) EP0804590A1 (fr)
JP (1) JPH09500783A (fr)
AU (1) AU6953394A (fr)
CA (1) CA2163427A1 (fr)
WO (1) WO1994028143A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009501019A (ja) * 2005-07-15 2009-01-15 メディカル リサーチ カウンシル 直交性リボソームｍＲＮＡペアに関する組成物および方法

Families Citing this family (266)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2204183A1 (fr) * 1994-11-01 1996-05-09 Andrew Lawrence Feldhaus Recepteurs chimeres servant a produire des lymphocites t cytotoxique th, activables selectivement independants des cellules auxiliaires
US6924128B2 (en) 1994-12-06 2005-08-02 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant AAV vectors
CA2188575A1 (fr) 1995-02-28 1996-09-06 H. Kirk Hammond Therapie angiogenique par transfert de genes
US20020103147A1 (en) 1997-09-05 2002-08-01 Hammond H. Kirk Gene therapy for congestive heart failure
US6752987B1 (en) 1995-02-28 2004-06-22 The Regents Of The University Of California Adenovirus encoding human adenylylcyclase (AC) VI
US6306830B1 (en) 1996-09-05 2001-10-23 The Regents Of The University Of California Gene therapy for congestive heart failure
AU7525496A (en) * 1995-10-23 1997-05-15 Betagene, Inc. Methods and compositions comprising glut-2 and glut-2 chimeras
US5910434A (en) * 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
US6642051B1 (en) 1997-10-21 2003-11-04 Targeted Genetics Corporation Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors
US6893865B1 (en) 1999-04-28 2005-05-17 Targeted Genetics Corporation Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles
US20040037811A1 (en) 2002-08-22 2004-02-26 The Cleveland Clinic Foundation Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy
WO2008121719A1 (fr) 2007-03-30 2008-10-09 The Cleveland Clinic Foundation Procédé de traitement des troubles ischémiques
US20050271639A1 (en) 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
US7384744B2 (en) 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
US7344886B2 (en) 2002-11-29 2008-03-18 Boehringer Ingelheim Pharma Gmbh & Co., Kg Neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product
WO2005007857A1 (fr) * 2003-07-21 2005-01-27 Transgene S.A. Polypeptide a activite cytosine-desaminase amelioree
US8669109B2 (en) 2003-08-19 2014-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methods of producing proteins in Chinese hamster ovary (CHO) cells
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
US20070003528A1 (en) 2005-06-29 2007-01-04 Paul Consigny Intracoronary device and method of use thereof
US20070036770A1 (en) 2005-08-12 2007-02-15 Wagner Darrell O Biologic device for regulation of gene expression and method therefor
EP1941043B1 (fr) 2005-10-21 2011-04-13 F. Hoffmann-La Roche AG Procede d'expression par recombinaison d'un polypeptide
EP1945781B1 (fr) 2005-10-28 2014-03-05 F.Hoffmann-La Roche Ag Expression de proteine dans des cellules de rongeur
CN101437933B (zh) 2005-12-28 2013-11-06 斯克里普斯研究所 作为药物靶标的天然反义和非编码的rna转录物
US20070190028A1 (en) 2006-02-13 2007-08-16 Jihong Qu Method and apparatus for heat or electromagnetic control of gene expression
CA2651478C (fr) 2006-05-17 2015-02-03 Josef Endl Cellules produisant des polypeptides
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
AU2008218925A1 (en) 2007-02-20 2008-08-28 Anaptysbio, Inc. Somatic hypermutation systems
US20090143288A1 (en) 2007-03-13 2009-06-04 Roche Palo Alto Llc Peptide-complement conjugates
CN101687920B (zh) 2007-06-29 2013-06-19 弗·哈夫曼-拉罗切有限公司 导致免疫球蛋白生产改善的重链突变体
SI2592148T1 (sl) 2007-10-12 2018-12-31 F. Hoffmann-La Roche Ag Izražanje beljakovin iz več nukleinskih kislin
US20100272679A1 (en) 2007-12-14 2010-10-28 Penn Marc S Compositions and methods of promoting wound healing
CA2762118A1 (fr) 2008-05-20 2010-01-28 Eos Neuroscience, Inc. Vecteurs pour la delivrance de proteines photosensibles et procedes d'utilisation
KR20110091796A (ko) 2008-12-04 2011-08-12 오피케이오 큐알엔에이, 엘엘씨 종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
JP6091752B2 (ja) 2008-12-04 2017-03-08 クルナ・インコーポレーテッド Ｅｐｏに対する天然アンチセンス転写物の抑制によるエリスロポエチン（ｅｐｏ）関連疾患の治療
US8927511B2 (en) 2008-12-04 2015-01-06 Curna, Inc. Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF
ES2560107T3 (es) 2009-02-12 2016-02-17 Curna, Inc. Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de cerebro (BDNF) por inhibición de transcrito antisentido natural para BDNF
EP2408919B1 (fr) 2009-03-16 2017-10-18 CuRNA, Inc. Traitement de maladies associées au facteur nucléaire 2 similaire au dérivé d'érythroïde 2 (nrf2) par inhibition de produit de transcription antisens naturel pour nrf2
MX2011009752A (es) 2009-03-17 2011-09-29 Opko Curna Llc Tratamiento de enfermedades relacionadas a homologo tipo delta 1(dlk1) por inhibicion de transcrito antisentido natural a homologo tipo delta (dlk1).
RU2537264C2 (ru) 2009-04-03 2014-12-27 Медикал Рисерч Каунсил Мутанты индуцируемой активацией цитидиндеаминазы (aid) и способы их применения
WO2010129799A2 (fr) 2009-05-06 2010-11-11 Curna, Inc. Traitement de maladies associées aux gènes du métabolisme et du transport des lipides par inhibition de transcrit antisens naturel d'un gène du métabolisme et du transport des lipides
JP6250930B2 (ja) 2009-05-06 2017-12-20 クルナ・インコーポレーテッド トリステトラプロリン（ｔｔｐ）に対する天然アンチセンス転写物の抑制によるｔｔｐ関連疾患の治療
JP5931720B2 (ja) 2009-05-08 2016-06-08 クルナ・インコーポレーテッド Ｄｍｄファミリーに対する天然アンチセンス転写物の抑制によるジストロフィンファミリー関連疾患の治療
US8957037B2 (en) 2009-05-18 2015-02-17 Curna, Inc. Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
KR101703695B1 (ko) 2009-05-22 2017-02-08 큐알엔에이, 인크. 전사 인자 ｅ3(ｔｆｅ3)에 대한 천연 안티센스 전사체의 억제에 의해 ｔｆｅ3 및 인슐린 수용체 기질 2(ｉｒｓ2)의 치료
CN103221541B (zh) 2009-05-28 2017-03-01 库尔纳公司 通过抑制抗病毒基因的天然反义转录物来治疗抗病毒基因相关疾病
JP5944311B2 (ja) 2009-06-16 2016-07-05 クルナ・インコーポレーテッド コラーゲン遺伝子に対する天然アンチセンス転写物の抑制によるコラーゲン遺伝子関連疾患の治療
US8951981B2 (en) 2009-06-16 2015-02-10 Curna, Inc. Treatment of paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1
ES2618894T3 (es) 2009-06-24 2017-06-22 Curna, Inc. Tratamiento de enfermedades relacionadas con el receptor del factor de necrosis tumoral 2 (tnfr2) por inhibición del transcrito natural antisentido para tnfr2
JP5907866B2 (ja) 2009-06-26 2016-04-26 クルナ・インコーポレーテッド ダウン症候群遺伝子に対する天然アンチセンス転写物の抑制によるダウン症候群遺伝子関連疾患の治療
CN102712925B (zh) 2009-07-24 2017-10-27 库尔纳公司 通过抑制sirtuin(sirt)的天然反义转录物来治疗sirtuin(sirt)相关性疾病
WO2011017516A2 (fr) 2009-08-05 2011-02-10 Curna, Inc. Traitement de maladies liées à un gène de l’insuline (ins) par inhibition du transcrit antisens naturel d'un gène de l'insuline (ins)
CN104313027B (zh) 2009-08-11 2018-11-20 库尔纳公司 通过抑制脂连蛋白(adipoq)的天然反义转录物治疗脂连蛋白(adipoq)相关疾病
EP2467482A4 (fr) 2009-08-21 2013-12-11 Curna Inc Traitement des maladies liées à « l'extrémité c de la protéine chip (protéine interagissant avec hsp70) » par inhibition du transcrit antisens naturel de chip
JP5964232B2 (ja) 2009-08-25 2016-08-03 カッパーアールエヌエー，インコーポレイテッド ‘ｉｑモチーフ含有ｇｔｐアーゼ活性化タンパク質’（ｉｑｇａｐ）に対する天然アンチセンス転写産物の阻害によるｉｑｇａｐ関連疾患の治療
CN102740894B (zh) 2009-08-28 2015-07-15 克利夫兰临床医学基金会 用于治疗缺血组织的sdf-1递送
DK2478107T3 (da) 2009-09-15 2019-01-02 Medimmune Ltd Celler til transient ekspression og anvendelser deraf
ES2664591T3 (es) 2009-09-25 2018-04-20 Curna, Inc. Tratamiento de enfermedades relacionadas con la filagrina (flg) mediante la modulación de la expresión y actividad del gen FLG
DK2513310T3 (en) 2009-12-16 2018-02-05 Curna Inc TREATMENT OF DISEASES CONNECTED WITH MEMBRANE-BONDED TRANSCRIPTION FACTOR Peptidase, site 1 (MBTPS1), BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTION TO MBTPS1
CA2782375C (fr) 2009-12-23 2023-10-31 Opko Curna, Llc Traitement de maladies associees a la proteine ucp2 (uncoupling protein) par inhibition du produit de transcription antisens naturel en ucp2
ES2661387T3 (es) 2009-12-23 2018-03-28 Curna, Inc. Tratamiento de enfermedades relacionadas con el factor de crecimiento de hepatocitos (hgf) mediante inhibición del transcrito antisentido natural a hgf
JP5993744B2 (ja) 2009-12-29 2016-09-14 カッパーアールエヌエー，インコーポレイテッド 核呼吸因子１（ｎｒｆ１）に対する天然アンチセンス転写物の阻害による核呼吸因子１関連疾患の治療
EP2519634B1 (fr) 2009-12-29 2016-06-01 CuRNA, Inc. Traitement de maladies liées à la protéine tumorale 63 (p63) par l'inhibition du produit de transcription antisens naturel de p63
DK2519632T3 (en) 2009-12-31 2018-07-23 Curna Inc TREATMENT OF INSULIN RECEPTOR SUBSTRATE 2- (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPTION TO IRS2 AND TRANSCRIPTION FACTOR E3 (TFE3)
DK2521784T3 (en) 2010-01-04 2018-03-12 Curna Inc TREATMENT OF INTERFERON REGULATORY FACTOR 8- (IRF8) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPT TO IRF8
KR101853509B1 (ko) 2010-01-06 2018-04-30 큐알엔에이, 인크. 췌장 발달 유전자에 대한 천연 안티센스 전사체의 억제에 의한 췌장 발달 유전자와 관련된 질환의 치료
KR101854926B1 (ko) 2010-01-11 2018-05-04 큐알엔에이, 인크. 성 호르몬 결합 글로불린 (ｓｈｂｇ)에 대한 자연 안티센스 전사체의 저해에 의한 성 호르몬 결합 글로불린 (ｓｈｂｇ) 관련된 질환의 치료
ES2671877T3 (es) 2010-01-25 2018-06-11 Curna, Inc. Tratamiento de enfermedades relacionadas con la RNASA (H1) mediante inhibición del transcrito antisentido natural a RNASA H1
ES2600356T3 (es) 2010-02-22 2017-02-08 Curna, Inc. Tratamiento de enfermedades relacionadas con pirrolin-5-carboxilato reductasa 1 (PYCR1) por inhibición de transcrito antisentido natural para PYCR1
US8980856B2 (en) 2010-04-02 2015-03-17 Curna, Inc. Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3
WO2011127088A2 (fr) 2010-04-05 2011-10-13 Eos Neuroscience, Inc. Procédés et compositions destinés à diminuer la douleur chronique
JP5978203B2 (ja) 2010-04-09 2016-08-24 カッパーアールエヌエー，インコーポレイテッド Ｆｇｆ２１に対する天然アンチセンス転写物の阻害による線維芽細胞増殖因子（ｆｇｆ２１）線維芽細胞増殖因子ｆｇｆ２１）関連疾患の治療
EP2957636B1 (fr) 2010-05-03 2020-04-01 CuRNA, Inc. Traitement de maladies liées à la sirtuine 3 (sirt3) par inhibition du transcrit antisens naturel de la sirt3
TWI586356B (zh) 2010-05-14 2017-06-11 可娜公司 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
US8895528B2 (en) 2010-05-26 2014-11-25 Curna, Inc. Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
DK2576784T3 (en) 2010-05-26 2018-02-26 Curna Inc TREATMENT OF METHIONIN SULPHOXIDE REDUCTASE A (MSRA) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTION TO MSRA
US8734780B2 (en) 2010-06-04 2014-05-27 Medtronic, Inc. Methods for treating cardiac pacing conditions
US20110305670A1 (en) 2010-06-10 2011-12-15 President And Fellows Of Harvard College Nucleic acid encoding fusion polypeptides that prevent or inhibit hiv infection
DK2585596T3 (da) 2010-06-23 2021-04-06 Curna Inc Behandling af spændingsreguleret natriumkanal-alpha-underenhed (scna)-relaterede sygdomme ved inhibering af naturligt antisense-transkript til scna
JP5998131B2 (ja) 2010-07-14 2016-09-28 カッパーアールエヌエー，インコーポレイテッド Ｄｉｓｃｓｌａｒｇｅｈｏｍｏｌｏｇ（ｄｌｇ）ｄｌｇ１への天然アンチセンス転写物の阻害によるｄｌｇ関連疾患の治療
US20120258496A1 (en) 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
US8993533B2 (en) 2010-10-06 2015-03-31 Curna, Inc. Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4
GB2498325B (en) 2010-10-15 2018-05-02 Eos Neuroscience Inc Engineered human GRM6 enhancer sequence for use in eye therapies
US9222088B2 (en) 2010-10-22 2015-12-29 Curna, Inc. Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA
WO2012068340A2 (fr) 2010-11-18 2012-05-24 Opko Curna Llc Compositions d'antagonat et leurs méthodes d'utilisation
JP6071893B2 (ja) 2010-11-23 2017-02-01 カッパーアールエヌエー，インコーポレイテッド Ｎａｎｏｇへの天然アンチセンス転写物の阻害によるｎａｎｏｇ関連疾患の治療
ES2653247T3 (es) 2011-06-09 2018-02-06 Curna, Inc. Tratamiento de enfermedades relacionadas con la frataxina (FXN) mediante inhibición del transcrito antisentido natural al gen FXN
MX365525B (es) 2011-09-06 2019-06-06 Curna Inc Compuestos que regulan la expresión de subunidades alfa de canales de sodio regulados por voltaje en enfermedades relacionadas con epilepsia mioclónica severa de la infancia.
EP2626369A1 (fr) 2011-11-24 2013-08-14 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Cellules souches mésenchymales conçues et leur utilisation thérapeutique
US20150071958A1 (en) 2011-11-30 2015-03-12 Board Of Trustees Of Michigan State University Immunological composition for clostridium difficile
HUE040179T2 (hu) 2012-03-15 2019-02-28 Curna Inc Agyi eredetû neutrotróf faktorral (Brain-derived neurotrophic factor, BDNF) összefüggõ betegségek kezelése a BDNF-fel kapcsolatos természetes antiszensz transzkriptumok gátlása révén
AU2013246034B2 (en) 2012-04-09 2017-12-07 Case Western Reserve University Compositions and methods for inhibiting the activity of LAR family phosphatases
KR20240136359A (ko) 2012-04-11 2024-09-13 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 B-세포 성숙 항원을 표적화하는 키메라 항원 수용체
TWI775096B (zh) 2012-05-15 2022-08-21 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
WO2013182553A2 (fr) 2012-06-06 2013-12-12 Boehringer Ingelheim International Gmbh Ingénierie cellulaire à l'aide d'arn
PT3824905T (pt) 2012-08-20 2025-03-21 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapêutica celular
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
WO2014102103A2 (fr) 2012-12-31 2014-07-03 Boehringer Ingelheim International Gmbh Intron hétérologue dans un peptide signal
WO2014102101A1 (fr) 2012-12-31 2014-07-03 Boehringer Ingelheim International Gmbh Séquences de nouveaux introns
EP2970956A1 (fr) 2013-03-11 2016-01-20 Novartis AG Procédé de recherche systématique de clones de cellules
US20160331809A1 (en) 2013-03-15 2016-11-17 Juventas Therapeutics, Inc. The use of sdf-1 to mitigate scar formation
WO2014152177A1 (fr) 2013-03-15 2014-09-25 Anthrogenesis Corporation Lymphocytes t modifiés
CN105339389B (zh) 2013-05-02 2021-04-27 安奈普泰斯生物有限公司 针对程序性死亡-1(pd-1)的抗体
AU2014297966B2 (en) 2013-07-31 2017-10-26 Novartis Ag Novel selection vectors and methods of selecting eukaryotic host cells
KR20160079854A (ko) 2013-10-31 2016-07-06 프레드 헛친슨 켄서 리서치 센터 변형된 조혈 줄기/선조 및 비-t 효과기 세포 및 이의 용도
WO2015092735A1 (fr) 2013-12-20 2015-06-25 Novartis Ag Nouvelles cellules eucaryotes et procédés d'expression par recombinaison d'un produit d'intérêt
EP3083677B1 (fr) 2013-12-20 2019-08-28 Novartis AG Nouvelles cellules eucaryotes et procédés d'expression de manière recombinante d'un produit d'intérêt
ES2866935T3 (es) 2014-01-10 2021-10-20 Anaptysbio Inc Anticuerpos dirigidos contra interleucina-33 (IL-33)
KR102537394B1 (ko) 2014-03-17 2023-05-30 애드베룸 바이오테크놀로지스, 인코포레이티드 원추세포에서 증강된 유전자 발현을 위한 조성물 및 방법
MA39867A (fr) 2014-04-23 2017-03-01 Juno Therapeutics Inc Procédés d'isolement, de culture et de manipulation génétique de populations de cellules immunitaires pour une thérapie adoptive
KR102307278B1 (ko) 2014-04-29 2021-09-30 노파르티스 아게 신규 척추동물 세포 및 관심 폴리펩티드의 재조합적 발현 방법
EP3149044B1 (fr) 2014-06-02 2020-10-21 The U.S.A. as represented by the Secretary, Department of Health and Human Services Récepteurs d'antigènes chimériques ciblant cd-19
US10738278B2 (en) 2014-07-15 2020-08-11 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
FI3757206T3 (fi) 2014-11-05 2024-06-19 Juno Therapeutics Inc Menetelmiä transduktoimiseksi ja solun prosessoimiseksi
WO2016086227A2 (fr) 2014-11-26 2016-06-02 The Regents Of The University Of California Compositions thérapeutiques comprenant des facteurs de transcription et leurs procédés de préparation et d'utilisation
CN107206025A (zh) 2014-12-03 2017-09-26 朱诺治疗学股份有限公司 用于过继细胞治疗的方法和组合物
MA41346A (fr) 2015-01-12 2017-11-21 Juno Therapeutics Inc Eléments régulateurs post-transcriptionnels d'hépatite modifiée
US20160208018A1 (en) 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
MY187898A (en) 2015-03-02 2021-10-27 Adverum Biotechnologies Inc Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
SI3277321T1 (sl) 2015-04-01 2024-11-29 Anaptysbio, Inc. Protitelesa, usmerjena proti t-celičnemu imunoglobulinu in mucin protein 3 (tim-3)
JP6913026B2 (ja) 2015-04-15 2021-08-04 アナプティスバイオ インコーポレイティッド インターロイキン３６受容体（ｉｌ−３６ｒ）に対する抗体
EP3995142A3 (fr) 2015-04-29 2022-08-24 Fred Hutchinson Cancer Center Cellules souches/progénitrices hématopoïétiques et effectrices non t modifiées, et leurs utilisations
WO2016176652A2 (fr) 2015-04-29 2016-11-03 Fred Hutchinson Cancer Research Center Cellules souches modifiées et leurs utilisations
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
EP3147366A1 (fr) 2015-09-25 2017-03-29 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Marqueur de sélection à base de récepteurs de mort
CA3002745A1 (fr) 2015-10-22 2017-04-27 Juno Therapeutics Gmbh Procedes, kits et appareil de culture de cellules
WO2017068425A1 (fr) 2015-10-22 2017-04-27 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
US11020429B2 (en) 2015-11-05 2021-06-01 Juno Therapeutics, Inc. Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
WO2017096329A1 (fr) 2015-12-03 2017-06-08 Juno Therapeutics, Inc. Récepteurs chimériques modifiés et compositions et procédés associés
EP3384294B1 (fr) 2015-12-04 2021-10-13 Juno Therapeutics, Inc. Méthodes et compositions liées à la toxicité associée à la thérapie cellulaire
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
MA71266A (fr) 2016-03-22 2025-04-30 Seattle Children's Hospital(DBA Seattle Children's Research Institute) Procédés d'intervention précoce pour prévenir ou améliorer la toxicité
JP2019513752A (ja) 2016-04-07 2019-05-30 ケース ウエスタン リザーブ ユニバーシティ 神経変性疾患を治療するためのｔｄｐ−４３のミトコンドリア局在化阻害剤
US11351270B2 (en) 2016-06-07 2022-06-07 University Of Iowa Research Foundation Junctophilin-2 fragments and uses therefor
JP7591342B2 (ja) 2016-06-08 2024-11-28 プレシゲン，インコーポレイテッド Ｃｄ３３特異的キメラ抗原受容体
AU2017301880C1 (en) 2016-07-29 2022-04-21 Juno Therapeutics, Inc. Immunomodulatory polypeptides and related compositions and methods
SG10202102061SA (en) 2016-08-29 2021-04-29 Univ Wayne State Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof
CN109790214B (zh) 2016-09-29 2022-09-06 豪夫迈·罗氏有限公司 用于选择产生多肽的细胞的改进方法
EP3519570B1 (fr) 2016-09-29 2022-06-08 F. Hoffmann-La Roche AG Procédé d'analyse et d'optimisation de modules d'édition génique et approches de délivrance
CN110139873A (zh) 2016-10-03 2019-08-16 朱诺治疗学股份有限公司 Hpv特异性结合分子
SG11201903282TA (en) 2016-10-13 2019-05-30 Juno Therapeutics Inc Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
CA3041684C (fr) 2016-11-01 2023-09-26 Anaptysbio, Inc. Anticorps diriges contre la mort programmee 1 (pd -1)
EP3689419A1 (fr) 2016-11-01 2020-08-05 AnaptysBio, Inc. Anticorps dirigés contre la protéine d'immunoglobuline de lymphocytes t et mucine 3 (tim-3)
CA3045323A1 (fr) 2016-12-02 2018-06-07 Juno Therapeutics, Inc. Cellules b modifiees et compositions et methodes associees
CA3045339A1 (fr) 2016-12-03 2018-06-07 Juno Therapeutics, Inc. Methodes et compositions pour l'utilisation de lymphocytes t therapeutiques en association avec des inhibiteurs de kinase
CN110382545A (zh) 2017-01-09 2019-10-25 泰萨罗公司 用抗pd-1抗体治疗癌症的方法
BR112019014169A2 (pt) 2017-01-09 2020-02-11 Tesaro, Inc. Métodos de tratamento de câncer com anticorpos anti-tim-3
JP7288401B2 (ja) 2017-01-10 2023-06-07 プレシゲン，インコーポレイテッド 新規の遺伝子スイッチ発現系を介したポリペプチドの発現のモジュレーション
US11517627B2 (en) 2017-01-20 2022-12-06 Juno Therapeutics Gmbh Cell surface conjugates and related cell compositions and methods
IL268349B2 (en) 2017-02-17 2024-08-01 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
US12440578B2 (en) 2017-02-22 2025-10-14 Io Biosciences, Inc. Nucleic acid constructs comprising gene editing multi-sites and uses thereof
US10828330B2 (en) 2017-02-22 2020-11-10 IO Bioscience, Inc. Nucleic acid constructs comprising gene editing multi-sites and uses thereof
MX2019010171A (es) 2017-02-27 2019-10-15 Juno Therapeutics Inc Composiciones, articulos de fabricacion y metodos relacionados con la dosificacion en la terapia celular.
AU2018251188A1 (en) 2017-04-14 2019-10-31 Juno Therapeutics, Inc. Methods for assessing cell surface glycosylation
MA49288A (fr) 2017-04-27 2020-03-04 Juno Therapeutics Gmbh Reactifs particulaires oligomères et leurs méthodes d'utilisation
AU2018265893B2 (en) 2017-05-12 2021-10-07 Ion Channel Innovations, Llc Compositions and methods for treating idiopathic overactive bladder syndrome and detrusor overactivity
JP7486953B2 (ja) 2017-05-18 2024-05-20 ユーエムセー・ユトレヒト・ホールディング・ベー・フェー 細胞標的化療法のための組成物および方法
WO2018223098A1 (fr) 2017-06-02 2018-12-06 Juno Therapeutics, Inc. Articles de fabrication et procédés liés à la toxicité associée à la thérapie cellulaire
JP2020522489A (ja) 2017-06-02 2020-07-30 ジュノー セラピューティクス インコーポレイテッド 養子細胞療法を用いる処置のための製造物品および方法
JP7262403B2 (ja) 2017-06-07 2023-04-21 プレシゲン，インコーポレイテッド 新規の細胞タグの発現
US20200230205A1 (en) 2017-07-11 2020-07-23 Case Western Reserve University Compositions and methods for treating myelin disorders
WO2019032927A1 (fr) 2017-08-09 2019-02-14 Juno Therapeutics, Inc. Procédés de production de compositions de cellules génétiquement modifiées et compositions associées
SG11202000966XA (en) 2017-08-11 2020-02-27 Boehringer Ingelheim Int Integration sites in CHO cells
WO2019070638A1 (fr) 2017-10-02 2019-04-11 Astrazeneca Ab Lignées cellulaires et méthodes pour une production accrue de protéines
MA50613A (fr) 2017-10-03 2020-08-12 Editas Medicine Inc Molécules de liaison spécifique à l'hpv
WO2019089858A2 (fr) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Procédés d'évaluation ou de surveillance d'une réponse à une thérapie cellulaire
MX2020004572A (es) 2017-11-01 2020-10-07 Juno Therapeutics Inc Receptores de antigenos quimericos especificos para el antigeno de maduracion de celulas b y polinucleotidos que codifican los mismos.
US11564946B2 (en) 2017-11-01 2023-01-31 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
SG11202003501XA (en) 2017-11-01 2020-05-28 Juno Therapeutics Inc Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
KR20200099137A (ko) 2017-11-06 2020-08-21 주노 쎄러퓨티크스 인코퍼레이티드 세포 요법 및 감마 세크레타제 억제제의 조합
CN112041430A (zh) 2017-12-08 2020-12-04 朱诺治疗学股份有限公司 用于培养细胞的无血清培养基配制品及其使用方法
CN119193493A (zh) 2017-12-08 2024-12-27 朱诺治疗学股份有限公司 生产工程化t细胞组合物的过程
AU2018379094B2 (en) 2017-12-08 2025-09-25 Juno Therapeutics, Inc. Phenotypic markers for cell therapy and related methods
KR20200110745A (ko) 2017-12-15 2020-09-25 주노 쎄러퓨티크스 인코퍼레이티드 항 - ｃｃｔ5 결합 분자 및 이의 사용 방법
IL275462B2 (en) 2017-12-22 2026-01-01 Genentech Inc Targeted integration of nucleic acids
IL314393A (en) 2018-03-06 2024-09-01 Precigen Inc Human papillomavirus vaccines and uses of the same
IL277128B2 (en) 2018-03-06 2025-11-01 Precigen Inc Hepatitis b vaccines and uses of the same
US12186343B2 (en) 2018-03-09 2025-01-07 Crage Medical Co., Limited Method and composition for treating tumors
WO2019178267A2 (fr) 2018-03-13 2019-09-19 University Of Iowa Research Foundation Régénération inductive des voies respiratoires par modulation du facteur transcriptionnel de cellules souches myoépithéliales glandulaires
US11471489B2 (en) 2018-04-05 2022-10-18 Juno Therapeutics, Inc. T cell receptors and engineered cells expressing same
WO2019219979A1 (fr) 2018-05-18 2019-11-21 Umc Utrecht Holding B.V. Compositions et procédés pour thérapies de ciblage de cellules
AU2019301053A1 (en) 2018-07-09 2021-01-28 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
WO2020033916A1 (fr) 2018-08-09 2020-02-13 Juno Therapeutics, Inc. Procédés pour évaluer des acides nucléiques intégrés
IL280659B2 (en) 2018-08-09 2024-11-01 Juno Therapeutics Inc Processes for generating engineered cells and compositions thereof
AU2019339464A1 (en) 2018-09-11 2021-03-25 Juno Therapeutics, Inc. Methods for mass spectrometry analysis of engineered cell compositions
CN112912392B (zh) 2018-10-26 2024-08-02 豪夫迈·罗氏有限公司 利用重组酶介导的盒式交换的多特异性抗体筛选方法
CN113227358A (zh) 2018-10-31 2021-08-06 朱诺治疗学有限公司 选择并刺激细胞的方法及用于所述方法的设备
AU2019372331A1 (en) 2018-11-01 2021-05-27 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
MX2021005021A (es) 2018-11-06 2021-08-11 Juno Therapeutics Inc Proceso para producir celulas t geneticamente modificadas.
KR20210111247A (ko) 2018-11-08 2021-09-10 주노 쎄러퓨티크스 인코퍼레이티드 치료 및 ｔ 세포 조절을 위한 방법 및 조합
KR20210094567A (ko) 2018-11-14 2021-07-29 유로반트 사이언시즈 게엠베하 평활근 기능장애의 치료를 위한 조성물 및 방법
EP3980544A1 (fr) 2018-12-21 2022-04-13 F. Hoffmann-La Roche AG Intégration ciblée d'acides nucléiques
AU2020215576A1 (en) 2019-01-29 2021-07-08 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ROR1)
EP3947437A1 (fr) 2019-03-29 2022-02-09 F. Hoffmann-La Roche AG Procédé de génération d'une cellule exprimant fcrn par intégration ciblée de multiples cassettes d'expression dans une organisation définie
SG11202111360YA (en) 2019-05-01 2021-11-29 Juno Therapeutics Inc Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
WO2020223571A1 (fr) 2019-05-01 2020-11-05 Juno Therapeutics, Inc. Cellules exprimant un récepteur chimérique à partir d'un locus cd247 modifié, polynucléotides et procédés associés
WO2020247648A2 (fr) 2019-06-05 2020-12-10 Anaptysbio, Inc. Agoniste pd-1 et son procédé d'utilisation
WO2020254356A1 (fr) 2019-06-19 2020-12-24 F. Hoffmann-La Roche Ag Procédé de génération d'une cellule exprimant un anticorps multivalent, bispécifique par intégration ciblée de multiples cassettes d'expression dans une organisation définie
AU2020294879A1 (en) 2019-06-19 2021-12-16 F. Hoffmann-La Roche Ag Method for the generation of a bivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
EP3986925A1 (fr) 2019-06-19 2022-04-27 F. Hoffmann-La Roche AG Procédé de génération d'une cellule exprimant un anticorps trivalent par intégration ciblée de multiples cassettes d'expression dans une organisation définie
CA3140297A1 (fr) 2019-06-19 2020-12-24 Simon Auslaender Procede de production d'une cellule exprimant une proteine par integration ciblee a l'aide d'arnm de cre
CA3140192A1 (fr) 2019-06-19 2020-12-24 Johannes Auer Procede de generation d'une cellule exprimant un anticorps multivalent, multispecifique par integration ciblee de multiples cassettes d'expression dans une organisation definie
WO2020264253A1 (fr) 2019-06-26 2020-12-30 Genentech, Inc. Intégration ciblée de configuration aléatoire d'acides nucléiques
JP7450647B2 (ja) 2019-06-26 2024-03-15 エフ． ホフマン－ラ ロシュ アーゲー Ｓｉｒｔ－１遺伝子ノックアウトを有する哺乳類細胞株
WO2021041994A2 (fr) 2019-08-30 2021-03-04 Juno Therapeutics, Inc. Procédés d'apprentissage automatique pour la classification de cellules
BR112022008023A2 (pt) 2019-10-30 2022-07-12 Juno Therapeutics Gmbh Dispositivos de seleção e/ou estimulação de células e métodos de uso
US12522645B2 (en) 2019-11-05 2026-01-13 Janssen Biotech, Inc. BCMA-targeted CAR-T cell therapy of multiple myeloma
US12570749B2 (en) 2019-12-06 2026-03-10 Juno Therapeutics, Inc. Anti-idiotypic antibodies to GPRC5D-targeted binding domains and related compositions and methods
US20230069055A1 (en) 2020-01-21 2023-03-02 Bolt Biotherapeutics, Inc Anti-pd-l1 antibodies
AU2021211669A1 (en) 2020-01-21 2022-08-25 Bolt Biotherapeutics, Inc. Anti-PD-L1 antibodies
KR20230005907A (ko) 2020-05-01 2023-01-10 볼트 바이오테라퓨틱스 인코퍼레이티드 항-dectin-2 항체
EP4150057A2 (fr) 2020-05-13 2023-03-22 Juno Therapeutics, Inc. Procédé de production de lots de cellules donneuses exprimant un récepteur recombinant
KR20230027043A (ko) 2020-06-24 2023-02-27 제넨테크, 인크. 핵산의 표적화 통합
KR20230042283A (ko) 2020-06-26 2023-03-28 주노 테라퓨틱스 게엠베하 재조합 수용체를 조건부로 발현하는 조작된 ｔ 세포, 관련된 폴리뉴클레오티드 및 방법
WO2022018178A1 (fr) 2020-07-24 2022-01-27 F. Hoffmann-La Roche Ag Procédé d'expression de fusion anticorps-multimère
WO2022026829A1 (fr) 2020-07-30 2022-02-03 Anaptysbio, Inc. Thérapie anti-récepteur de l'interleukine 36 (il-36r) pour traiter la toxicité cutanée
AU2021319103A1 (en) 2020-07-30 2023-02-09 Anaptysbio, Inc. Anti-interleukin 36 receptor (IL-36r) therapy for ichthyosis
TW202223092A (zh) 2020-09-24 2022-06-16 瑞士商赫孚孟拉羅股份公司 具有基因剔除的哺乳動物細胞株
CA3197726A1 (fr) 2020-10-15 2022-04-21 Simon Auslaender Constructions d'acides nucleiques ameliorees pour activation de genes simultanee
HRP20250766T1 (hr) 2020-10-15 2025-08-15 F. Hoffmann - La Roche Ag Konstrukti nukleinske kiseline za transkripciju va rna
CA3196493A1 (fr) 2020-10-23 2022-04-28 Martin Edward DAHL Modulateurs d'attenuateur de lymphocytes b et t (btla) et leur methode d'utilisation
WO2022098787A1 (fr) 2020-11-04 2022-05-12 Juno Therapeutics, Inc. Cellules exprimant un récepteur chimérique à partir d'un locus de chaîne de la superfamille des immunoglobines cd3 invariable modifié, polynucléotides et procédés associés
WO2022116086A1 (fr) 2020-12-03 2022-06-09 Janssen Biotech, Inc. Thérapie du myélome multiple basée sur des cellules car-t ciblées par bcma
CN116670282A (zh) 2020-12-22 2023-08-29 豪夫迈·罗氏有限公司 靶向xbp1的寡核苷酸
EP4314814A1 (fr) 2021-03-22 2024-02-07 Juno Therapeutics, Inc. Procédés de détermination de la puissance d'une composition de cellules thérapeutiques
KR20240018454A (ko) 2021-05-06 2024-02-13 주노 테라퓨틱스 게엠베하 T 세포의 자극 및 형질도입 방법
EP4148067A1 (fr) 2021-09-08 2023-03-15 F. Hoffmann-La Roche AG Procédé d'expression d'une fusion anticorps-multimère
WO2023081752A1 (fr) 2021-11-04 2023-05-11 Janssen Biotech, Inc. Thérapie du myélome multiple basée sur des cellules car-t ciblées par bcma
WO2023077343A1 (fr) 2021-11-04 2023-05-11 Janssen Biotech, Inc. Thérapie du myélome multiple basée sur des cellules car-t ciblées par bcma
JP2025500443A (ja) 2021-12-22 2025-01-09 ジェネンテック， インコーポレイテッド 多重ベクターリコンビナーゼ媒介カセット交換
KR20240141180A (ko) 2022-01-14 2024-09-25 사카로 아이엔씨. 탈-n-아세틸화 폴리시알산(dpsa) 결합제 및 그의 사용 방법
KR20240158888A (ko) 2022-02-28 2024-11-05 얀센 바이오테크 인코포레이티드 다발성 골수종을 위한 bcma를 표적으로 하는 car-t 세포 요법
US20250213721A1 (en) * 2022-03-24 2025-07-03 Memorial Sloan-Kettering Cancer Center Compositions including ifne and uses thereof
WO2023198685A1 (fr) 2022-04-13 2023-10-19 F. Hoffmann-La Roche Ag Procédé de détermination de génomes d'aav
JP2025513335A (ja) 2022-04-19 2025-04-24 エフ． ホフマン－ラ ロシュ アーゲー 改良された産生細胞
KR20250007603A (ko) 2022-04-27 2025-01-14 아납티스바이오, 아이엔씨. B 및 t 림프구 감쇠제(btla) 조절제 및 이를 사용하는 방법
US20250297282A1 (en) 2022-05-05 2025-09-25 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
JP2025517572A (ja) 2022-06-03 2025-06-05 エフ． ホフマン－ラ ロシュ アーゲー 改良された産生細胞
WO2023232922A1 (fr) 2022-06-03 2023-12-07 F. Hoffmann-La Roche Ag Procédé de production de particules d'aav recombinées
US20250382640A1 (en) 2022-06-29 2025-12-18 Juno Therapeutics, Inc. Lipid nanoparticles for delivery of nucleic acids
CN120530136A (zh) 2022-11-07 2025-08-22 安奈普泰斯生物有限公司 Cd122结合剂和其使用方法
WO2024100604A1 (fr) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Procédés de fabrication de cellules immunitaires modifiées
EP4619511A1 (fr) 2022-11-15 2025-09-24 Genentech, Inc. Intégration médiée par transposon combinée et intégration ciblée d'acides nucléiques dans des cellules hôtes
IL320073A (en) 2022-11-23 2025-06-01 Hoffmann La Roche Method for increasing recombinant protein expression
EP4630782A1 (fr) 2022-12-09 2025-10-15 Juno Therapeutics, Inc. Procédés d'apprentissage automatique pour prédire un phénotype cellulaire au moyen d'une imagerie holographique
US20240240175A1 (en) 2023-01-12 2024-07-18 Genentech, Inc. Combinatorial vector cloning and transfection strategies for targeted integration of nucleic acids
EP4658675A1 (fr) 2023-02-03 2025-12-10 C3S2 GmbH Procédés de fabrication non virale de cellules immunitaires modifiées
CN121311765A (zh) 2023-04-18 2026-01-09 朱诺治疗学股份有限公司 评估治疗性细胞组合物的效力的细胞毒性测定
CA3205511A1 (en) 2023-04-19 2025-03-17 Janssen Biotech, Inc. Bcma-targeted car-t cell therapy for multiple myeloma
WO2024233783A1 (fr) 2023-05-09 2024-11-14 Cornell University Codage de cassette d'expression pour facteur de croissance endothéliale vasculaire
AU2024269420A1 (en) 2023-05-11 2025-11-27 Case Western Reserve University Anxiolytic therapy
KR20260026101A (ko) 2023-05-23 2026-02-25 주노 쎄러퓨티크스 인코퍼레이티드 T 세포의 활성화 마커 및 t 세포 활성화를 평가하는 방법
WO2024243594A1 (fr) 2023-05-25 2024-11-28 Anaptysbio, Inc. Agoniste de btla pour la modulation de cellules dendritiques
AU2024287644A1 (en) 2023-07-12 2026-01-29 Saccharo, Inc. De-n-acetylated polysialic acid (dpsa) binding agent, conjugates, and method of using same
CN121666400A (zh) 2023-08-09 2026-03-13 豪夫迈·罗氏有限公司 单特异性和多特异性抗trem2抗体、其方法和用途
WO2025032069A1 (fr) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Anticorps anti-trem2 mono et multispécifiques, procédés et utilisations associés
TW202530413A (zh) 2023-10-05 2025-08-01 美商健生生物科技公司 用於生產ｃａｒ－ｔ細胞藥品之慢病毒製造的改良方法
WO2025085705A1 (fr) 2023-10-18 2025-04-24 Genentech, Inc. Lignées cellulaires de production d'ovaire de hamster chinois à particules de type rétroviral
US20250207106A1 (en) 2023-12-20 2025-06-26 Genentech, Inc. Composition and methods for adeno-associated virus producing stable human embryonic kidney-293 cell lines
WO2025147545A1 (fr) 2024-01-03 2025-07-10 Juno Therapeutics, Inc. Nanoparticules lipidiques pour l'administration d'acides nucléiques et procédés et utilisations associés
US20250269024A1 (en) 2024-02-05 2025-08-28 Legend Biotech Usa Inc. Bcma-targeted car-t cell therapy for multiple myeloma
US20250339527A1 (en) 2024-03-12 2025-11-06 Legend Biotech Usa Inc. Bcma-targeted car-t cell therapy for multiple myeloma
WO2025212519A1 (fr) 2024-04-01 2025-10-09 Moonlight Bio, Inc. Protéines de liaison au dll3 et leurs utilisations
WO2025215060A1 (fr) 2024-04-11 2025-10-16 F. Hoffmann-La Roche Ag Anticorps se liant spécifiquement à des oligonucléotides modifiés
WO2025262318A1 (fr) 2024-06-21 2025-12-26 Boehringer Ingelheim International Gmbh Inactivation multi-hydrolase

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2018273C (fr) * 1989-06-09 1999-04-06 Peter D. Senter Cytosine deaminase thermostable
AU650085B2 (en) * 1990-11-13 1994-06-09 Immunex Corporation Bifunctional selectable fusion genes
US5358866A (en) * 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
AU675948B2 (en) * 1992-05-01 1997-02-27 United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Bystander effect tumoricidal therapy

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009501019A (ja) * 2005-07-15 2009-01-15 メディカル リサーチ カウンシル 直交性リボソームｍＲＮＡペアに関する組成物および方法

Also Published As

Publication number Publication date
AU6953394A (en) 1994-12-20
WO1994028143A1 (fr) 1994-12-08
CA2163427A1 (fr) 1994-12-08
EP0804590A1 (fr) 1997-11-05

Similar Documents

Publication Publication Date Title
JPH09500783A (ja) シトシンデアミナーゼ（ｃｄ）遺伝子に基づく二機能性選択融合遺伝子
AU650085B2 (en) Bifunctional selectable fusion genes
US6949242B2 (en) Retroviral vector for the transfer and expression of genes for therapeutic purposes in eukaryotic cells
US6027722A (en) Vectors for gene transfer
Lim et al. Retrovirus-mediated gene transfer of human adenosine deaminase: expression of functional enzyme in murine hematopoietic stem cells in vivo
US6287863B1 (en) Method of transferring a DNA sequence to a cell in vitro
Belmont et al. Expression of human adenosine deaminase in murine hematopoietic cells
CA2160034C (fr) Vecteurs retroviraux a base du virus de la leucemie du gibbon
US6872528B2 (en) Highly productive packaging lines
JP2001512689A (ja) Ｔ細胞を遺伝子改変するための方法
EP2138580A1 (fr) Vecteur pour une thérapie génique
US6576463B1 (en) Hybrid vectors for gene therapy
US5698446A (en) Methods and compositions for inhibiting production of replication competent virus
JP2020500562A (ja) ムコ多糖症ｉｉ型のための遺伝子治療
JP2000514284A (ja) Ｓａｒエレメントを有するベクター
JPH10510995A (ja) 胚細胞発現のためのレトロウイルスベクター
JPH11511651A (ja) 遺伝子治療に特に適した改良型レトロウイルスベクター
US6555370B1 (en) Bifunctional selectable fusion genes
Bernstein et al. Genetic engineering of mouse and human stem cells
Gelinas et al. Long-Term Expression of the Human ß-Globin Gene After Retroviral Transfer into Pluripotent Hematopoietic Stem Cells of the Mouse
US20030190753A1 (en) Vectors for gene transfer
EP2138584A1 (fr) Gènes à enveloppe virale mousseuse
CA2199131C (fr) Hybrides vectoriels retroviraux et leur utilisation pour le transfert de genes